Triple-negative breast cancer (TNBC) accounts for approximately 15–20% of breast cancer cases and is defined by the negative expression of estrogen receptor, progestogen receptor (PR) and human epidermal growth factor receptor 2 (HER2) [2–4]. Here, ERBB2 is linked to triple-negative breast carcinoma.